Official journal of the Slovak Society of Cardiology,
Slovak Society of Hypertension and Slovak Association for Cardiac Arrhythmias

Cardiology Letters 2020, 29(3):183-194

Animal models of pulmonary hypertension

Trubačová S1, Kováčová D1, Klimas J2, Paulis Ľ1, 3
1 Ústav patologickej fyziológie, Lekárska fakulta Univerzita Komenského v Bratislave
2 Katedry farmakológie a toxikológie, Farmaceutická fakulta Univerzity Komenského v Bratislave
3 Ústav normálnej a patologickej fyziológie, Centrum experimentálnej medicíny SAV, Bratislava, Slovenská republika

Pulmonary hypertension is a disease characterized by an increase in mean arterial pressure in the pulmonary artery and a primary or secondary pulmonary arterial remodeling, particularly narrowing and obstruction of small pulmonary arteries. With the progressive increase in afterload, right ventricular hypertrophy, subsequent dilatation and right heart failure develop. The etiological and pathophysiological heterogeneity of this disease, as well as unsatisfactory treatment options, call for adequate animal models of each type of pulmonary hypertension. A relatively wide range of animal models is available, but they do not always completely simulate the development of clinical disease and its aspects. For example, pulmonary hypertension induced in rodents is not manifested by a marked change in hemodynamic parameters, hypertrophy or right ventricular failure. Several classical models do not lead to the development of pulmonary arterial hypertension characterized by plexogenic arteriopathy, and the success rate of therapeutic intervention in these models does not always reflect their clinical efficacy. Nevertheless, the range of models available may contribute to the study of the initial stages of pulmonary hypertension, which are more difficult to follow in clinical situation due to late diagnosis. The development of new and refining of existing models is a useful tool for elucidating the pathophysiological mechanisms of pulmonary hypertension, as well as a platform for preclinical testing of innovative therapeutic interventions. Therefore, our manuscript provides an overview of the evolution of the most commonly used animal models and their contribution to the field of pulmonary hypertension study.

Keywords: pulmonary hypertension; animal model; right ventricle failure; remodeling of pulmonary arteries

Published: March 1, 2020  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Trubačová S, Kováčová D, Klimas J, Paulis Ľ. Animal models of pulmonary hypertension. Cardiology Letters. 2020;29(3):183-194.
Download citation

References

  1. Simonneau G, Gatzoulis MA, Adatia I, et al. Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 2013;62:D34-D41. Go to original source...
  2. Galiè N, Humbert M, Vachiery JL, et al. ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 2015;37:ehv317.
  3. Hoeper MM, Humbert M, Souza R, et al. A global view of pulmonary hypertension. Lancet Respir Med 2016;4: 306-322. Go to original source...
  4. Sztrymf B, Souza R, Bertoletti L, et al. Prognostic factors of acute heart failure in patients with pulmonary arterial hypertension. Eur. Respir. J 2010;35:1286-1293. Go to original source...
  5. Maarman G, Lecour S, Butrous G, et al. A comprehensive review: the evolution of animal models in pulmonary hypertension research; are we there yet? Pulm. Circ 2013;3:739-756. Go to original source...
  6. Doggrell SA, Brown L. Rat models of hypertension, cardiac hypertrophy and failure. Cardiovasc. Res 1998;39:89-105. Go to original source...
  7. Tuder RM, Archer SL, Dorfmüller P, et al. Relevant issues in the pathology and pathobiology of pulmonary hypertension. J Am Coll Cardiol 2013;62: D4-D12. Go to original source...
  8. Colvin KL, Yeager ME. Animal models of pulmonary hypertension: matching disease mechanisms to etiology of the human disease. J. Pulm. Respir. Med 2014;4:4.
  9. Stenmark KR, Meyrick B, Galiè N, et al. Animal models of pulmonary arterial hypertension: the hope for etiological discovery and pharmacological cure. Am J Physiol Lung Cell Mol Physiol 2009;297:L1013-L1032. Go to original source...
  10. Šimková I. Nové formy liečby pľúcnej hypertenzie. Via pract. 2008;5:252-255.
  11. Luknár M, Lesný P, Varga I, et al. Princípy modernej liečby pľúcnej artériovej hypertenzie. Cardiology Lett. 2012;1:192-200.
  12. Luknár M, Lesný P, Gonçalvesová E. Risk stratification in pulmonary artery hypertension: the way to better outcomes. Cardiology Lett. 2019;28:26-32.
  13. Kay JM, Heath D, Smith P, et al. Fulvine and the pulmonary circulation. Thorax 1971;26:249-261. Go to original source...
  14. Kay JM. Dietary pulmonary hypertension. Thorax 1994;49:S33-S38. Go to original source...
  15. Kay JM, Harris P, Heath D. Pulmonary hypertension produced in rats by ingestion of Crotalaria spectabilis seeds. Thorax 1967;22:176-179. Go to original source...
  16. Chesney CF, Allen JR. Monocrotaline induced pulmonary vascular lesions in non-human primates. Cardiovasc Res 1973;7:508518. Go to original source...
  17. Chesney CF, Allen JR. Endocardial fibrosis associated with monocrotaline-induced pulmonary hypertension in nonhuman primates (Macacaarctoides). Am J Vet Res 1973;34:1577-1581. Go to original source...
  18. Reid MJ, Lamé MW, Morin D, et al. Involvement of cytochrome P450 3A in the metabolism and covalent binding of 14 C monocrotaline in rat liver microsomes. J Biochem Mol Toxicol1998;12:157-166t Go to original source...
  19. Wilson DW, Segall HJ, Pan LC, et al. Mechanisms and pathology of monocrotaline pulmonary Toxicity. Crit Rev Toxicol 1992;22:307-325. Go to original source...
  20. Gomez-Arroyo JG, Farkas L, Alhussaini AA, et al. The monocrotaline model of pulmonary hypertension in perspective. Am J Physiol Lung Cell Mol Physiol 2012;302: L363-L369. Go to original source...
  21. Pan LC, Lamé MW, Morin D, et al. Redblood cells augment transport of reactive metabolites of monocrotaline from liver to lung in isolated and tandem liver and lung preparations. Toxicol Appl Pharmacol 1991;110:336-346. Go to original source...
  22. Schoental R, Head MA. Pathological changes in rats as a result of treatment with monocrotaline. Br. J. Cancer 1955;9:229-237. Go to original source...
  23. Nogueira-Ferreira R, Vitorino R, Ferreira R, et al. Exploring the monocrotaline animal model for the study of pulmonary arterial hypertension: A network approach. Pulm. Pharmacol. Ther. 2015;35:8-16. Go to original source...
  24. Thomas HC, Lame MW, Dunston SK. et al. Monocrotaline pyrrole induces apoptosis in pulmonary artery endothelial cells, Toxicol. Appl. Pharmacol 1998;151:236-244. Go to original source...
  25. Lappin PB, Ross KL, King LE, et. al. The response of pulmonary vascular endothelial cells to monocrotaline pyrrole: cell proliferation and DNA synthesis in vitro and in vivo. Toxicol. Appl. Pharmacol 1998;150:37-48. Go to original source...
  26. Sehgal PB, Mukhopadhyay S. Dysfunctional intracellular trafficking in the pathobiology of pulmonary arterial hypertension. Am J Respir Cell Mol Biol 2007;37:31-37. Go to original source...
  27. Huang J, Wolk JH, Gewitz MH, et al. Progressive endothelial cell damage in an inflammatory model of pulmonary hypertension. Exp Lung Res 2010;36:57-66. Go to original source...
  28. Frasch HF, Marshall C, Marshall BE. Endothelin-1 is elevated in monocrotaline pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol 1999;276:L304-L310. Go to original source...
  29. Tyler RC, Muramatsu M, Abman SH, et al. Variable expression of endothelial NO synthase in three forms of rat pulmonary hypertension. Am. J. Physiol. Lung Cell Mol. Physiol 1999;276:L297-L303. Go to original source...
  30. Lappin PB, Roth RA. Hypertrophy and prolonged DNA synthesis in smooth muscle cells characterize pulmonary arterial wall thickening after monocrotaline pyrrole administration to rats. Toxicol. Pathol 1997;25: 372-380. Go to original source...
  31. Guignabert C, Raffestin B, Benferhat R, et al. Serotonin transporter inhibition prevents and reverses monocrotaline-induced pulmonary hypertension in rats. Circulation 2005;111:28122819. Go to original source...
  32. McMurtry MS, Bonnet S, Wu X. Dichloroacetate prevents and reverses pulmonary hypertension by inducing pulmonary artery smooth muscle cell apoptosis. Circ. Res 2004;95:830-840. Go to original source...
  33. Zakrzewicz A, Kouri FM, Nejman B, et al. The transforming growth factor-β/Smad 2,3 signalling axis is impaired in experimental pulmonary hypertension. Eur Respir J 2007;29:1094-1104. Go to original source...
  34. Ramos MF, Lamé MW, Segalland HJ, et al. Smad signaling in the rat model of monocrotaline pulmonary hypertension. Toxicol. Pathol 2008;36:311-320. Go to original source...
  35. Dahal KB, Kosanovic D, Kaulen C, et al. Involvement of mast cells in monocrotaline-induced pulmonary hypertension in rats. Respir. Res. 2011;12:60. Go to original source...
  36. Savai R, Pullamsetti SS, Kolbe J, et al. Immune and inflammatory cell involvement in the pathology of idiopathic pulmonary arterial hypertension. Am. J. Respir. Crit. Care Med. 2012;186:897-908. Go to original source...
  37. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012;141:210-221. Go to original source...
  38. Heath D, Yacoub M. Lung mast cells in plexogenic pulmonary arteriopathy. J Clin Pathol 1991;44:1003-1006. Go to original source...
  39. Vajner L, Vytásek R, Lachmanová V, et al. Acute and chronic hypoxia as well as 7-day recovery from chronic hypoxia affects the distribution of pulmonary mast cells and their MMP-13 expression in rats. Int J Exp Pathol 2006;87:83-391. Go to original source...
  40. Malikova E, Galkova K, Vavrinec P. et al. Local and systemic renin-angiotensin system participates in cardiopulmonary-renal interactions in monocrotaline-induced pulmonary hypertension in the rat. Mol Cell Biochem. 2016;418:147-157. Go to original source...
  41. Cowan KN, Heilbut A, Humpl T, et al. Complete reversal of fatal pulmonary hypertension in rats by a serine elastase inhibitor. Nat Med 2000;6:698-702. Go to original source...
  42. Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J. Clin. Investig 2005;115:2811-2821. Go to original source...
  43. Nagaoka T, Fagan KA, Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171:494-499. Go to original source...
  44. Jiang BH, Tawara S, Abe K, et al. Acute vasodilator effect of fasudil, a Rho kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007;49:85-89. Go to original source...
  45. Tawara S, Fukumoto Y, Shimokawa H. Effects of combined therapy with a Rho-kinase inhibitor and prostacyclin on monocrotaline-induced pulmonary hypertension in rats. J Cardiovasc Pharmacol 2007;50:195-200. Go to original source...
  46. Clozel M, Hess P, Rey M, et al. Bosentan, sildenafil, and their combination in the monocrotaline model of pulmonary hypertension in rats. Exp Biol Med 2006;231:967-973.
  47. Cui B, Cheng YS, Dai DZ, et al. CPU0213, a non-selective ETA/ETB receptor antagonist, improves pulmonary arteriolar remodeling of monocrotaline-induced pulmonary hypertension in rats. Clin Exp Pharmacol Physiol 2009;36:169-175. Go to original source...
  48. Schermuly RT, Kreisselmeier KP, Ghofrani HA, et al. Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 2004;169:3945. Go to original source...
  49. Tanaka Y, Schuster DP, Davis EC, et al. The role of vascular injury and hemodynamics in rat a. pulmonary artery remodeling. J. Clin. Investig1996;98:434-442. Go to original source...
  50. Katz MG, Fargnoli AS, Gubara SM, et al. The left pneumonectomy combined with monocrotaline or sugen as a model of pulmonary hypertension in rats. JoVE 2019;145:e59050. Go to original source...
  51. White RJ, Meoli DF, Swarthout RF. et al. Plexiform-like lesions and increased tissue factor expression in a rat model of severe pulmonary arterial hypertension. Am J Physiol Lung Cell Mol Physiol 2007;293:L583-L590. Go to original source...
  52. Happé CM, de Raaf MA, Rol N, et al. Pneumonectomy combined with SU5416 induces severe pulmonary hypertension in rats. Am J Physiol Lung Cell Mol Physiol 2016;310:L1088-L1097. Go to original source...
  53. Vachiery JL, Adir Y, Barbera JA, et al. Pulmonary hypertension due to left heart disease. J Am Coll Cardiol 2013;62:D100-D108. Go to original source...
  54. Simkova I, Urbanova J. Pulmonary function alterations after correction of mitral stenosis. Bratisl Lek Listy 2001;102: 78-281. Go to original source...
  55. Dai ZK, Wu BN, Chen IC, et al. Attenuation of pulmonary hypertension secondary to left ventricular dysfunction in the rat by Rho-kinase inhibitor fasudil. Pediatr Pulmonol. 2011;46:45-59. Go to original source...
  56. Ranchoux B, Nadeau V, Bourgeois A, et al. Metabolic syndrome exacerbates pulmonary hypertension due to left heart disease. Circ. Res2019;125:449-466. Go to original source...
  57. Chen Y, Guo H, Xu D, et al. Left ventricular failure produces profound lung remodeling and pulmonary hypertension in mice: heart failure causes severe lung disease. Hypertension 2012;59:1170-1178. Go to original source...
  58. Xiong PY, Potus F, Chan W, et al. Models and molecular mechanisms of World Health Organization Group 2 to 4 pulmonary hypertension. Hypertension, 2018;71:34-55. Go to original source...
  59. Fujimoto Y, Urashima T, Kawachi F, et al. Pulmonary hypertension due to left heart disease causes intrapulmonary venous arterialization in rats. Thorac Cardiovasc Surg. 2017;154:1742. e8-1753. Go to original source...
  60. Hislop A, Reid L. New findings in pulmonary arteries of rats with hypoxia-induced pulmonary hypertension. Br J ExpPathol1976;57:542-554.
  61. Rabinovitch M, Gamble W, Nadas AS, et al. Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. Am J Physiol Heart Circ Physiol 1979;236:H818-H827. Go to original source...
  62. Stenmark KR, Fasules J, Hyde DM, et al. Severe pulmonary hypertension and arterial adventitialc hanges in newborn calves at 4,300 m. J. Appl. Physiol1987;62:821-830. Go to original source...
  63. Stenmark KR, Fagan KA, Frid MG. Hypoxia-induced pulmonary vascular remodeling. Circ. Res2006;99:675-691. Go to original source...
  64. Muramatsu M, Tyler RC, Gutkowska J, et al. Atrial natriuretic peptide accounts for in creased cGMP in hypoxia-induced hypertensive rat lungs. Am J Physiol Lung Cell Mol Physiol 1997; 272:L1126-L1132. Go to original source...
  65. Ooi H, Cadogan E, Sweeney M, et al. Chronic hypercapnia inhibits hypoxic pulmonary vascular remodeling. Am J Physiol Heart Circ Physiol 2000;278:H331-H338. Go to original source...
  66. Howell K, Preston RJ, McLoughlin P. Chronic hypoxia causes angiogenesis in addition to remodelling in the adult rat pulmonary circulation. J Physiol 2003;547: 33-145. Go to original source...
  67. Choudhary G, Troncales F, Martin D, et al. Bosentan attenuates right ventricular hypertrophy and fibrosis in normobaric hypoxia model of pulmonary hypertension. J Heart Lung Transplant 2011;30:827-833. Go to original source...
  68. Ryan J, Bloch K, Archer SL. Rodent models of pulmonary hypertension: harmonisation with the world health organisation's categorisation of human PH. Int J Clin Pract Suppl. 2011;65:1534. Go to original source...
  69. Drexler E, Bischoff J, Slifka A, et al. Stiffening of the extrapulmonary arteries from rats in chronic hypoxic pulmonary hypertension. J Res Nat Inst Stand Technol 2008;113:239-249. Go to original source...
  70. Hoshikawa Y, Nana-Sinkam P, Moore MD, et al. Hypoxia induces different genes in the lungs of rats compared with mice. Physiol Genomics 2003;12:209-219. Go to original source...
  71. Xia XD, Xu ZJ, Hu XG, et al. Impaired iNOS-sGC-cGMP signalling contributes to chronic hypoxic and hypercapnic pulmonary hypertension in rat. Cell Biochem Funct. 2012;30:279-285. Go to original source...
  72. Burke DL, Frid MG, Kunrath CL, et al. Sustained hypoxia promotes the development of a pulmonary artery-specific chronic inflammatory microenvironment. Am J Physiol Lung Cell Mol Physiol 2009;297:L238-L250. Go to original source...
  73. Pugliese SC, Poth JM, Fini MA, et al. The role of inflammation in hypoxic pulmonary hypertension: from cellular mechanisms to clinical phenotypes. Am J Physiol Lung Cell Mol Physiol 2015;308:L229-L252. Go to original source...
  74. Voelkel NF, Tuder RM. Hypoxia-induced pulmonary vascular remodeling: a model for what human disease? The J Clin Invest2 000;106:733-738.
  75. Bauer NR, Moore TM, McMurtry IF. Rodent models of PAH: are we there yet? Am J Physiol Lung Cell Mol Physiol 2007;293:L580-L582. Go to original source...
  76. Morimatsu Y, Sakashita N, Komohara Y, et al. Development and characterization of an animal model of severe pulmonary arterial hypertension. J VascRes 2012;49:33-42. Go to original source...
  77. Orton EC, Reeves JT, Stenmark KR. Pulmonary vasodilation with structurally altered pulmonary vessels and pulmonary hypertension. J Appl Physiol 1988;65:2459-2467. Go to original source...
  78. Kentera D, Susic D, Veljkovic V, et al. Pulmonary artery pressure in rats with hereditary platelet function defect. Respiration 1988;54:110-114. Go to original source...
  79. Sato K, Webb S, Tucker A, et al. Factors influencing the idiopathic development of pulmonary hypertension in the fawn hooded rat. Am Rev Respir Dis 1992;145:793-797. Go to original source...
  80. Bonnet S, Michelakis ED, Porter CJ, et al. An abnormal mitochondrial-hypoxia inducible factor-1alpha-Kv channel pathway disrupts oxygen sensing and triggers pulmonary arterial hypertension in fawn hooded rats: similarities to human pulmonary arterial hypertension. Circulation 2006;113:2630- 2641. Go to original source...
  81. LeCras TD, Kim DH, Gebb S, et al. Abnormal lung growth and the development of pulmonary hypertension in the fawn-hooded rat. Am J Physiol Lung Cell Mol Physiol 1999;277:L709-L718. Go to original source...
  82. Zamora MR, Stelzner TJ, Webb S, et al. Over expression of endothelin-1 and enhanced growth of pulmonary artery smooth muscle cells from fawn-hooded rats. Am J Physiol Lung Cell Mol Physiol 1996;270:L101-L109. Go to original source...
  83. Taraseviciene-Stewart L, Kasahara Y, Alger L, et al. Inhibition of the VEGF receptor 2 combined with chronic hypoxia causes cell death-dependent pulmonary endothelial cell proliferation and severe pulmonary hypertension. FASEB J 2001;15:427438. Go to original source...
  84. Ciuclan L, Bonneau O, Hussey M, et al. A novel murine model of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2011;184:1171-1182. Go to original source...
  85. Lown JW, Sim SK. The mechanism of the bleomycin-induced cleavage of DNA. Biochem Biophys Res Commun 1977;77:11501157. Go to original source...
  86. Sebti SM, Mignano JE, Jani JP, et al. Bleomycinhydrolase: molecular cloning, sequencing, and biochemical studies reveal membership in the cysteineproteinase family. Biochemistry 1989;28:6544-6548. Go to original source...
  87. Umezawa H, Ishizuka M, Maeda K, et al. Studies on bleomycin. Cancer 1967;20:891-895. Go to original source...
  88. Yagoda A, Mukherji B, Young C, et al. Bleomycin, an antitumorantibiotic. Clinical experience in 274 patients. Ann Intern Med 1972;77:861-870. Go to original source...
  89. Adamson IY, Bowden DH. The pathogenesis of bloemycin-induced pulmonary fibrosis in mice. Am J Pathol 1974;77:185-197.
  90. Thrall RS, McCormick JR, Jack RM, et al. Bleomycin-induced pulmonary fibrosis in the rat: inhibition by indomethacin. Am J Pathol. 1979;95:117-130.
  91. Chaudhary NI, Schnapp A, Park JE. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med 2006; 73:769-776. Go to original source...
  92. Mungunsukh O, Griffin AJ, Lee YH, et al. Bleomycin induces the extrinsic apoptic pathway in pulmonary endothelial cells. Am J Physiol Lung Cell Mol Physiol 2010;298:L696-L703. Go to original source...
  93. Hemnes AR, Zaiman A, Champion HC. PDE5A inhibition attenuates bleomycin-induced pulmonary fibrosis and pulmonary hypertension through inhibition of ROS generation and RhoA/ Rho kinasea ctivation. Am J Physiol Lung Cell Mol Physiol. 2008;294:L24-L33. Go to original source...
  94. Schroll S, Arzt M, Sebah D, et al. Improvement of bleomycininduced pulmonary hypertension and pulmonary fibrosis by the endothelin receptor antagonist bosentan. Respir Physiol Neurobiol. 2010;170:32-36. Go to original source...
  95. Rathinasabapathy A, Bruce E, Espejo A, et al. Therapeutic potential of adipose stem cell-derived conditioned medium against pulmonary hypertension and lung fibrosis. Br. J. Pharmacol 2016;173:2859-2879. Go to original source...
  96. Chung MP, Monick MM, Hamzeh NY, et al. Role of repeated lung injury and genetic background in bleomycin-induced fibrosis. Am J Respir Cell Mol Biol 2003;29:375-380. Go to original source...
  97. Walkin L, Herrick SE, Summers A, et al. The role of mouse strain differences in the susceptibility to fibrosis: a systematic review. Fibrogenesis & tissue repair 2013;6:18. Go to original source...
  98. Lang IM, Pesavento R, Bonderman D, et al. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Respir J 2013;41:462-468. Go to original source...
  99. Dartevelle P, Fadel E, Mussot S, et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004;23: 637-648. Go to original source...
  100. Hoeper MM, Mayer E, Simonneau G, et al. Chronic thromboembolic pulmonary hypertension. Circulation 2006;113:2011-2020. Go to original source...
  101. Auger WR, Fedullo PF. Chronic thromboembolic pulmonary hypertension. Semin Respir Crit Care Med 2009;30:471-483. Go to original source...
  102. Pepke-Zaba J, Delcroix M, Lang I, et al. Chronic thromboembolic pulmonary hypertension (CTEPH): results from an international prospective registry. Circulation 2011;124:1973-1981. Go to original source...
  103. Remkova A, Simkova I, Valkovicova T. Platelet abnormalities in chronic thromboembolic pulmonary hypertension. Int. J. Clin. Exp. Med. 2015;8:9700.
  104. Yaoita N, Shirakawa R, Fukumoto Y, et al. Platelets are highly activated in patients of chronic thromboembolic pulmonary hypertension. Arterioscler Thromb Vasc Biol 2014;34:2486-2494. Go to original source...
  105. Morris TA, Marsh JJ, Chiles PG, et al. High prevalence of dysfibrinogenemia among patients with chronic thromboembolic pulmonary hypertension. Blood 2009;114:1929-1936. Go to original source...
  106. Sharma S, Lang IM. Current understanding of the pathophysiology of chronic thromboembolic pulmonary hypertension. Thromb. Res2 018;164:136-144.
  107. Toshner M, Pepke-Zaba J. Chronic thromboembolic pulmonary hypertension: time for research in pathophysiology to catch up with developments in treatment. F1000 Prime Reports 2014,6:38. Go to original source...
  108. Mercier O, Fadel E. Chronic thromboembolic pulmonary hypertension: animal models. Eur Respir J 2013;41:1200-1206. Go to original source...
  109. Moser KM, Guisan M, Bartimmo EE, et al. In vivo and post mortem dissolution rates of pulmonary emboli and venous thrombi in the dog. Circulation 1973;48:170-178. Go to original source...
  110. Moser KM, Cantor JP, Olman M, et al. Chronic pulmonary thromboembolism in dogs treated with tranexamic acid. Circulation 1991;83:1371-1379. Go to original source...
  111. Mulchrone A, Kellihan HB, Forouzan O, et al. A large animal model of right ventricular failure due to chronic thromboembolic pulmonary hypertension: a focus on function. Frontiers in cardiovascular medicine 2018;5:189. Go to original source...
  112. Sato H, Hall CM, Griffith GW, et al. Large animal model of chronic pulmonary hypertension ASAIO J 2008;54:396-400. Go to original source...
  113. Mercier O, Tivane A, Raoux F, et al. A reliable piglet model of chronic thrombo-embolic pulmonary hypertension. Am J Respir Crit Care Med 2011;183:A2415. Go to original source...
  114. Arias-Loza PA, Jung P, Abeßer M, et al. Development and characterization of an inducible rat model of chronic thromboembolic pulmonary hypertension novelty and significance. Hypertension 2016;67:1000-1005. Go to original source...
  115. Neto-Neves, EM, Brown MB, Zaretskaia MV, et al. Chronic embolic pulmonary hypertension caused by pulmonary embolism and vascular endothelial growth factor inhibition. Am J Pathol2017;187:700-712. Go to original source...
  116. Karpov A, Anikin N, Cherepanov D, et al. 3311 a new rat model of chronic thromboembolic pulmonary hypertension induced by repeated intravenous administration of biodegradable alginate microspheres. Eur. Heart J. 2019;40:ehz745-0075. Go to original source...
  117. Beppu H, Ichinose F, Kawai N, et al. BMPR-II heterozygous mice have mild pulmonary hypertension and an impaired pulmonary vascular remodeling response to prolonged hypoxia. Am J Physiol Lung Cell Mol Physiol 2004;287:L1241-L1247. Go to original source...
  118. Yasuda T, Tada Y, Tanabe N, et al. Rho-kinase inhibition alleviates pulmonary hypertension in transgenic mice expressing a dominant-negative type II bone morphogenetic protein receptor gene. Am J Physiol Lung Cell Mol Physiol 2011;301:L667-L674. Go to original source...
  119. Ivy D, McMurtry IF, Yanagisawa M, et al. Endothelin B receptor deficiency potentiates ET-1 and hypoxic pulmonay vasoconstriction. Am J Physiol Lung Cell Mol Physiol 2001; 80:L1040-L1048. Go to original source...
  120. Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007; 115(10): 1260-1268. Go to original source...
  121. Welches WR, Brosnihan KB, Ferrario CM. A comparison of the properties and enzymatic activities of three angiotensin processing enzymes: angiotensin converting enzyme, prolylendopeptidase and neutralendopeptidase 24.11. Lifesciences 1993;52:1461-1480. Go to original source...
  122. Dempsey EC, Wick MJ, Karoor V, et al. Neprilysin null mice develop exaggerated pulmonary vascular remodeling in response to chronic hypoxia. Am J Pathol 2009;174:782-796. Go to original source...
  123. Ambartsumian N, Klingelhöfer J, Grigorian M, et al. Tissuespecific post-transcriptional down-regulation of expression of the S100A4 (mts1) gene in transgenic animals. Invasion Metastasis 1998;18:96-104. Go to original source...
  124. Ambartsumian N, Grigorian M, Lukanidin E. Genetically modified mouse models to study the role of metastasis promoting S100A4 (mts1) protein in metastatic mammary cancer. J DairyRes 2005;72: 27-33. Go to original source...
  125. Ebralidze A, Tulchinsky E, Grigorian M, et al. Isolation and characterization of a gene specifically expressed in different metastatic cells and whose deduced gene product has a high degree of homology to a Ca2+-binding protein family. Genes&development 1989;3:1086-1093. Go to original source...
  126. Greenway S, van Suylen RJ, Sarvaas GDM, et al. S100A4/Mts1 produces murine pulmonary artery changes resembling plexogenic arteriopathy and is increased in human plexogenic arteriopathy. Am J Pathol 2004;164: 253-262. Go to original source...
  127. Dempsie Y, Nilsen M, White K, et al. Development of pulmonary arterial hypertension in mice over-expressing S100A4/Mts1 is specific to females. Respres 2011;12:159. Go to original source...
  128. Merklinger SL, Wagner RA, Spiekerkoetter E, et al. Increased fibulin-5 and elastin in S100A4/Mts1 mice with pulmonary hypertension. Circ. Res 2005;97:596-604. Go to original source...
  129. MacLean MR, Dempsie Y. Serotonin and pulmonary hypertension - from bench to bedside? Curr Opin Pharmacol 2009;9:281-286. Go to original source...
  130. Eddahibi S, Humbert M, Fadel E, et al. Serotonin transporter over expression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J ClinInvest 2001;108:1141-1150. Go to original source...
  131. Soon E, Holmes AM, Treacy CM, et al. Elevated levels of inflammatory cytokines predict survival in idiopathic and familial pulmonary arterial hypertension. Circulation 2010;122:920-927. Go to original source...
  132. Price LC, Wort SJ, Perros F, et al. Inflammation in pulmonary arterial hypertension. Chest 2012;141: 210-221. Go to original source...
  133. Steiner MK, Syrkina OL, Kolliputi N, et al. Interleukin-6 over expression induces pulmonary hypertension. Circ. Res2009;104:236-244. Go to original source...